The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Emotional blunting with bupropion and serotonin reuptake inhibitors in three randomized controlled trials for acute major depressive disorder
Abstract
Background Emotional blunting is theorized to be an adverse effect of antidepressants, particularly serotonin reuptake inhibitors, but this has not been firmly established. Another possibility is that emotional blunting represents a residual depressive symptom. Methods We analyzed data from adult outpatients with acute major depressive disorder who participated in three 8-week randomized controlled trials. Trials 1 and 2 were pooled (venlafaxine, n = 378; bupropion, n = 389; placebo, n = 383) and Trial 3 (escitalopram, n = 254; bupropion, n = 260) was analyzed separately. Emotional blunting was measured with the "inability to feel" item from the Montgomery-Åsberg Depression Rating Scale. Results Emotional responsiveness improved, on average, in all treatment groups. Only a minority of participants (≤6 %) experienced more emotional blunting post-treatment, compared to baseline, with no significant differences between treatment groups, although roughly 20-25 % continued to report an inability to feel normal emotions at the final assessment. In Trials 1 and 2, emotional blunting was associated with poorer outcomes in terms of depressive symptoms, suicidal ideation, and sexual function, but these correlations were nearly identical in the placebo group. Limitations The trials were short and cannot speak to the possibility of emotional blunting from long-term treatment. Emotional blunting was measured with a single item. Conclusions The study medications did not significantly decre…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Thase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0803 · Cited by 304
Keller, A., McGarvey, E. L., & Clayton, A. H. (2006) · Journal of Sex & Marital Therapy · doi:10.1080/00926230500232909 · Cited by 243
Emotional blunting with antidepressant treatments: A survey among depressed patients
Goodwin, G. M., Price, J., De Bodinat, C., & Laredo, J. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.05.048 · Cited by 202
Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity
Vaishnavi, S. N., Nemeroff, C. B., Plott, S. J., Rao, S. G., Kranzler, J., & Owens, M. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.07.006 · Cited by 178
Read, J., Cartwright, C., & Gibson, K. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.01.042 · Cited by 150
Price, J., Cole, V., Doll, H., & Goodwin, G. M. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.030 · Cited by 81
Hewett, K., Chrzanowski, W., Schmitz, M., Savela, A., Milanova, V, Gee, M., Krishen, A., Millen, L., Leary, M., & Modell, J. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089602 · Cited by 57
Research works printed but not linked: 14
- Asçibasi, 2020, Evaluation of emotional adverse effects of antidepressants: a follow-up study, J. Clin. Psychopharmacol., 40, 594, 10.1097/JCP.0000000000001300 · DOI
- Bymaster, 2001, Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors, Neuropsychopharmacology, 25, 871, 10.1016/S0893-133X(01)00298-6 · DOI
- Christensen, 2021, Validation of the Oxford depression questionnaire: sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting, J. Affect. Disord., 294, 924, 10.1016/j.jad.2021.07.099 · DOI · Paper page
- Debonnel, 2007, Differential physiological effects of a low dose and high doses of venlafaxine in major depression, Int. J. Neuropsychopharmacol., 10, 51, 10.1017/S1461145705006413 · DOI
- Goldsmith, 2011, The psychoactive effects of antidepressants and their association with suicidality, Curr. Drug Saf., 6, 115, 10.2174/157488611795684622 · DOI
- Hamilton, 1960, A rating scale for depression, J. Neurol. Neurosurg. Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
- Hewett, 2010, Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR, J. Psychopharmacol., 24, 1209, 10.1177/0269881109106953 · DOI
- Moncrieff, 2018, Against the stream: antidepressants are not antidepressants–an alternative approach to drug action and implications for the use of antidepressants, BJPsych Bull., 42, 42, 10.1192/bjb.2017.11 · DOI
- Montgomery, 1979, A new depression scale designed to be sensitive to change, Br. J. Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
- Opbroek, 2002, Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses?, Int. J. Neuropsychopharmacol., 5, 147, 10.1017/S1461145702002870 · DOI · Paper page
- Owens, 2008, Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine, Neuropsychopharmacology, 33, 3201, 10.1038/npp.2008.47 · DOI · Paper page
- Serretti, 2009, Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis, J. Clin. Psychopharmacol., 29, 259, 10.1097/JCP.0b013e3181a5233f · DOI · Paper page
- Shen, 2019, Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: results from a randomized, double-blind, non-inferiority trial, J. Affect. Disord., 257, 143, 10.1016/j.jad.2019.07.023 · DOI
- Stahl, 2004, A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor, Prim.Care CompanionJ.Clin.Psychiatry, 6, 159
Cited by
Sorted by citations
Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review
Dang, V., Sambuco, N., Yammine, L., & Versace, F. (2026) · doi:10.64898/2026.01.31.702984 · Cited by 4
Kato, M., Kikuchi, T., Watanabe, K., Sumiyoshi, T., Moriguchi, Y., Åström, D., & Christensen, M. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s428443 · Cited by 3
Nazir, N., Nazir, D., Mehmood, R., Wani, Z. A., & Raj, R. (2026) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_201_25 · Cited by 2
Metadata
- Authors
- Peters, E. M., Balbuena, L., & Lodhi, R. J.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 318
- Pages
- 29-32
- ISSN
- 0165-0327
- Cited by
- 13
- References
- 9
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
